Cure Vac's m RNA vaccine for influenza
GPTKB entity
Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:benefits |
rapid production
|
| gptkbp:capacity |
scalable production
|
| gptkbp:challenges |
scientific and logistical challenges
|
| gptkbp:clinical_trial |
gptkb:various_countries
Phase 1 healthy adults pending Phase 2 multiple phases planned |
| gptkbp:collaborations |
academic institutions
international research teams various research institutions |
| gptkbp:developed_by |
gptkb:Cure_Vac_AG
|
| gptkbp:future_plans |
potential for pandemic response
|
| gptkbp:healthcare |
potential to reduce influenza cases
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cure Vac's m RNA vaccine for influenza
|
| gptkbp:is_effective_against |
under investigation
|
| gptkbp:is_vulnerable_to |
gptkb:educational_campaigns
ongoing government grants continuous monitoring to be determined ongoing clinical trials refrigerated conditions lipid nanoparticle preventive vaccine B-cell response T-cell response global distribution plans m RNA technology advancement requires further studies |
| gptkbp:manager |
intramuscular injection
|
| gptkbp:market |
high demand for influenza vaccines
|
| gptkbp:operating_hours |
two doses
|
| gptkbp:outcome |
safety
immunogenicity |
| gptkbp:partnerships |
pharmaceutical companies
|
| gptkbp:produced_by |
gptkb:Company
|
| gptkbp:receives_funding_from |
public and private investments
private investors |
| gptkbp:regulatory_compliance |
not approved
|
| gptkbp:research |
regulatory hurdles
|
| gptkbp:research_focus |
preclinical studies
influenza prevention |
| gptkbp:safety_features |
under evaluation
|
| gptkbp:scientific_goals |
improve vaccine response
|
| gptkbp:shelf_life |
limited shelf life
|
| gptkbp:shipping_options |
lipid nanoparticles
|
| gptkbp:target_audience |
general population
|
| gptkbp:targets |
gptkb:virus
seasonal influenza strains |
| gptkbp:technology |
m RNA technology
|
| gptkbp:bfsParent |
gptkb:Cure_Vac_AG
|
| gptkbp:bfsLayer |
4
|